DETECT
AND TREAT AF
REDUCE
HIGH-ENERGY SHOCKS
HOW MULTIPULSE THERAPY WORKS
How MultiPulse Therapy can potentially detect and treat atrial fibrillation (AF), rapid ventricular tachycardia (VT) and ventricular fibrillation (VF).

FIND OUT MORE Explore the latest innovation in tachyarrhythmia technology.

ABOUT US
Advancing cardioversion and defibrillation using low-energy therapy
Cardialen, Inc. is an early-stage medical device company dedicated to advancing implantable cardioversion and defibrillation using low energy for use as a first-line therapy to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks.
Our MultiPulse™ Therapy (MPT) is currently being studied in an FDA-approved early feasibility IDE clinical trial exploring how a sequence of low-energy pulses timed to stop abnormal heart rhythms may restore normal heart rhythm using less energy than current high-energy shocks.
CAUTION: Investigational Device. Limited by Federal (United States) law to investigational use only
SENIOR LEADERSHIP
Jeff Peters, President and CEO
Sumeet Dham, VP Research & Development
Michelle Straight, Director of Quality
BOARD OF DIRECTORS
Jeff Peters, President and CEO; Director
Jay Schmelter, RiverVest Venture Partners, LLC; Director
William Schmidt, Cultivation Capital; Director
Anna French, PhD, Qiming Venture Partners; Director
LEARN MORE ABOUT CLINICAL TRIALS
If you are a patient or physician interested in learning more about clinical trials, please contact us.
Cardialen, Inc.
6160 Summit Drive North, Suite 450
Minneapolis, Minnesota 55430
612.208.1260
Get directions
Media contact
Michael Walsh
EMPLOYMENT INQUIRIES
Interested in joining the Cardialen team?
Please complete the form.